Study With Various Immunotherapy Treatments in Participants With Lung Cancer
← catalyst calendarNCT05676931 · readout ≤ 499 d
Sponsored by Gilead Sciences (industry) · GILD — their whole pipeline →. With Arcus Biosciences, Inc..
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
400estimated
Sites
53
Countries
Australia, France, Georgia +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-02-21 | actual | When the study began enrolling |
| Primary completion | Dec 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2023-01-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced Non-Small Cell Lung Cancer
Interventions
- Drug: Domvanalimab
- Drug: Quemliclustat
- Drug: Zimberelimab
- Drug: Docetaxel
- Drug: Platinum-Based Doublet
Primary outcomes
what the primary-completion date above is the date OFObjective response rate (ORR) as measured by Response Evaluation Criteria in Solid Tumors (RECIST v1.1)
measured Up to 58 months
The incidence and severity of adverse events (AEs) and serious adverse events (SAEs)
measured Up to 58 months
Permalink · GILD's whole pipeline · Catalyst calendar · Every registered study · What changed